Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma

Article Obstetrics & Gynecology

Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies

Linyuan Wang et al.

Summary: PTEN plays a central role in the pathogenesis of endometrial carcinoma. PTEN IHC shows moderate accuracy in predicting loss of function PTEN mutations, and can be used for diagnostic purposes.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2022)

Add to Collection

Article Oncology

Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer

Stephanie Lheureux et al.

Summary: This study explored the combination of immunotherapy and antiangiogenic agents in the treatment of endometrial cancer. Adding cabozantinib to nivolumab significantly improved outcomes in heavily pretreated endometrial cancer patients. The identification of immunotherapy-pretreated patients based on baseline immune profiling can help determine who might benefit from combination treatment with antiangiogenics.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer

Panagiotis A. Konstantinopoulos et al.

Summary: This study evaluated the potential positive outcomes and safety of a combination therapy using the polyadenosine diphosphate-ribose polymerase inhibitor talazoparib and the programmed cell death ligand 1 (PD-L1) inhibitor avelumab in recurrent MMRP EC. The results suggest that this combination therapy showed a favorable toxic effect profile and met the predetermined criteria for further evaluation in MMRP EC.

JAMA ONCOLOGY (2022)

Add to Collection

Article Obstetrics & Gynecology

To Test or Re-Test, that is the Question: Comparison of the Mismatch Repair Deficiency between Primary and Recurrent Sites of Uterine Cancers (088)

Daniel Spinosa et al.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Obstetrics & Gynecology

Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies

Linyuan Wang et al.

Summary: This study aimed to reevaluate PTEN immunohistochemistry (IHC) pattern in comparison to next-generation sequencing for identifying PTEN abnormality. The results showed that PTEN IHC had high sensitivity, specificity, and accuracy in predicting loss of function PTEN mutation. PTEN abnormalities were associated with histotype and molecular subtype of endometrial carcinoma and were common across all molecular subtypes of endometrioid carcinomas. The findings support the use of PTEN IHC for diagnostic purposes in endometrial neoplasms, but complementary testing of both IHC and sequencing of PTEN should be considered for clinical trial design.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2022)

Add to Collection

Article Oncology

New approaches for targeting platinum-resistant ovarian cancer

Michelle McMullen et al.

Summary: Platinum drugs are crucial in ovarian cancer treatment, but resistance is a major challenge, with complex mechanisms involving both intracellular and microenvironment factors. Clinical trials are essential for improving outcomes, and future research should focus on understanding the biology of the disease and enhancing quality of life and survival for patients.

SEMINARS IN CANCER BIOLOGY (2021)

Add to Collection

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer

Elizabeth M. Swisher et al.

Summary: The study found that a significant proportion of HGOC patients who responded to the PARP inhibitor rucaparib had long-term responses, with most of them harboring BRCA1 or BRCA2 mutations, particularly BRCA structural variants. Patients with BRCA structural variants had significantly longer duration of response compared to those with other mutation types, indicating a relationship between this specific mutation type and treatment response. Additionally, patients with high genome-wide LOH without BRCA mutations also exhibited long-term responses, suggesting potential molecular characteristics associated with treatment outcomes.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma

Joyce F. Liu et al.

Summary: Adavosertib monotherapy showed encouraging and durable evidence of activity in women with USC, with a progression-free survival rate of 47.1% at 6 months and an objective response rate of 29.4%. The study suggests that Adavosertib may be an effective treatment option for USC patients and further investigation is warranted.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Editorial Material Oncology

Wee1 Inhibition in Recurrent Serous Uterine Cancer: Science Paving the Way in a Challenging Disease

Ainhoa Madariaga et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

Elizabeth M. Swisher et al.

Summary: RAD51C, RAD51D mutations, and high-level BRCA1 promoter methylation can predict response to the PARP inhibitor rucaparib, while BRCA1 methylation loss may be a major cross-resistance mechanism to platinum and PARPi.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Obstetrics & Gynecology

A randomized, phase ii study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer

B.J. Rimel

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Obstetrics & Gynecology

A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer

Vicky Makker et al.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).

Deborah Smith et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?

N. Y. L. Ngoi et al.

Summary: The recognition of homologous recombination deficiency in high-grade serous ovarian cancer has led to the development of PARP inhibitors as an important therapy. However, controversies exist around defining and evaluating HRD, and the dynamic nature of tumoral HRD status poses challenges. It is critical to optimize HRD testing to maximize the potential benefits of PARP inhibitors for patients with HGSOC.

ESMO OPEN (2021)

Add to Collection

Editorial Material Oncology